Money maintenance · the annual audit
The renewal review: the 30-minute annual audit that August 2026 just proved necessary
Set a calendar event for your plan’s anniversary month and run five checks: (1) your real price — pull the last three statements and compare against what you think you pay; (2) your provider’s current price — their public page today versus your grandfathered rate, in both directions; (3) your molecule’s availability — this year a major platform exited compounded tirzepatide mid-subscription, teaching everyone that “can they still dispense it” is a real question; (4) the market — fifteen minutes against the corrected index, where this month’s re-verification moved one major provider from a remembered $149 to a real $297 and repriced another’s freedom tier to ~$449; (5) your coverage — open enrollment can flip the whole cash-versus-covered equation (~$25-class copays beat every cash lane). Thirty minutes, once a year, against dated sources. Below: each check operationalized, the switch/stay decision tree, and why this site’s own August corrections are the case study. Compounded pricing referenced throughout involves non-FDA-approved formulations.
Checks 1–2 — price drift runs both directions
Subscription drift is real in both directions and both are worth catching. Upward drift hides in dose-tier graduations you consented to in a checkout flow eleven months ago, in “membership” lines that appeared during a platform migration, and in promo rates that quietly matured — the annualization file catalogs the shapes. Pull three statements; the number on them is your price, whatever the marketing page says. Downward drift is the one nobody checks: the market’s floor moved down through 2025–2026, several programs cut published rates, and grandfathered customers can be paying above the current door rate at their own provider — a two-line email (“I see new customers pay X; please match it on my account”) has one of the best effort-to-savings ratios in this entire subject. Flat-priced plans make both checks trivial — the audited $139/$119 pair should show twelve identical statements, and any deviation is itself the finding.
Check 3 — availability risk became real this year
March 2026: a major platform settled with a brand manufacturer and exited compounded tirzepatide, and a real population of mid-course subscribers discovered their renewal question wasn’t price but existence. The annual audit now includes: is my molecule still on my provider’s formulary; has their pharmacy network changed (re-run the verification if names changed); and what does their communication history look like when things changed — a provider that emailed clearly about a formulary shift is showing you its crisis behavior in advance. If your provider carries only one molecule, the switch playbook is your contingency file; if they carry both under flat pricing, your contingency is already priced in.
Check 4 — the fifteen-minute market re-shop, with this month as the case study
The reason annual re-verification is a discipline and not paranoia: memory rots and markets move. This site’s own August 17 research pass corrected a remembered $149 to a documented $297 month-to-month at one major provider (its real budget number being the ~$197 non-refundable-prepay rate — read that file first), repriced another’s no-commitment tirzepatide to ~$449, logged a brand-entry shift toward ~$299, and added five new entrants including a written-flat $249.99 no-commitment lane — all in one afternoon of checking primary sources. Your fifteen minutes: open the index, note the verification dates, spot-check your provider’s own page, and compare your true recurring number against the tier-labeled field. If your rate beats the audited floors, you’re done in five. If it doesn’t, the boards — sema, tirz — rank the alternatives by verified value, not vibes. The audited benchmark to beat ↗
Check 5 — coverage season outranks everything
Every cash number in this audit loses to a covered one: with commercial insurance and an active savings card, brand therapy at ~$25-class copays computes to the best value in the market, certificates included. Open enrollment is the annual audit’s highest-stakes line: formularies change yearly, employer plans add and drop GLP-1 coverage in waves, and a denial that stood last year may fall to this year’s appeal. Fifteen additional minutes during your enrollment window — checking the new formulary, the new prior-auth criteria, your accumulator status — can retire the entire cash question for a year.
The stay-or-switch decision, compressed
Stay when your audited-or-verified rate is within ~$15/month of the field’s best for your molecule, your provider passed the availability and communication checks, and switching costs (new intake, records transfer, titration continuity) would eat a year of savings. Negotiate then stay when the only gap is grandfathered pricing above the current door. Switch when the gap exceeds ~$25/month against a higher-verification-tier alternative, when your molecule’s availability wobbled, or when terms hardened (prepay lock-ins, refund language) — and switch on your schedule, before renewal, never in a coverage gap. The meta-rule the corrections taught: dates beat memory — whatever you decide, decide it against this year’s numbers.
FAQ
How often should I re-shop my GLP-1 provider?
A structured thirty-minute review annually, plus a trigger review whenever your provider changes price, pharmacy, terms, or formulary mid-year.
Can I ask my current provider to match their new-customer price?
Yes — grandfathered rates above the current door price are common, and a short written match request is routinely honored. Get the answer in writing either way.
What changed in the August 2026 corrections?
Re-verification against primary sources moved one provider’s remembered $149 to a real $297 (with a ~$197 non-refundable prepay), repriced no-commitment tirzepatide to ~$449, shifted brand entry toward ~$299, and added five new verified-tier entrants — the working proof that annual re-checking is worth thirty minutes.